NasdaqGS:GRALBiotechs
GRAIL (GRAL) Could Be 5% Overvalued As FDA Review Date Sharpens Focus
Regulatory milestone puts focus on GRAIL stock
GRAIL (GRAL) is in the spotlight after the FDA scheduled a September 23, 2026 advisory committee meeting to review the Premarket Approval application for its Galleri multi cancer early detection blood test.
See our latest analysis for GRAIL.
The FDA panel date has come alongside GRAIL’s recent Q2 update and a sharp 1 day share price return of 9.59%, even though the year to date share price return is down 21.82%. Over the past year, the total...